Vinorelbine is a common chemotherapy medication to treat mesothelioma and other types of cancer. It is used as a single agent or with a combination of mesothelioma treatments.
Commonly used as a chemotherapy treatment, vinorelbine is meant for aggressive cancers like metastatic breast cancer, non-small cell lung cancer, and mesothelioma. The medication comes from the alkaloids extracted from the rosy periwinkle plant, scientifically known as Catharanthus roseus.
French pharmacist Pierre Potier and his team invented the chemotherapy medication in the 1980s. France approved the medication in 1989 for lung cancer treatment and for breast cancer treatment in 1991.
The United States first approved vinorelbine for non-small cell lung cancer treatment in 1994. The medication remains on the World Health Organization’s List of Essential Medicines.
Cancer patients often use Navelbine, a brand name of vinorelbine.
Cancerous tumors spread by cell division (mitosis). The function of vinorelbine is to stop cell division by disrupting the body’s microtubules, which are structures that contribute to cell production.
Chemotherapy cannot tell the difference between cancerous cells and healthy cells, leading to its side effects. While the medication stops the spread of malignant blood cells, mitosis of healthy cells slows.
Doctors administer the chemotherapy by injection into a vein or by mouth. Patients typically receive the medication in six-week cycles with a combination of another chemotherapy drug, depending on the patient’s health.
Doctors may use vinorelbine as a form of palliative therapy to improve the quality of life for mesothelioma patients who may not tolerate other cancer treatments.
Doctors may use vinorelbine as second-line therapy in patients with recurrent mesothelioma who have already received standard chemotherapy as a treatment option.
Since the treatment disrupts normal cell function, some patients may experience side effects. However, most patients do not experience all of the side effects, and most doctors can predict how long they will last.
Side effects do not influence the effectiveness of the medication, and there are options to minimize or prevent them. About 30 percent of patients receiving this treatment experience side effects. Common side effects include:
Less common side effects are:
This treatment is typically low in toxicity compared to other chemotherapy treatments. However, the medication may affect specific organs in the body.
Mild to moderate nerve damage may occur in patients who use this form of treatment, resulting in reduced or abnormal touch sensation.
About 12 percent of patients who are administered this medication experience mild, sudden hair loss. Patients may also experience injection site reactions, including pain or vein discoloration.
Some patients may experience shortness of breath during or after treatment.
If you have mesothelioma and want to learn more about vinorelbine, talk to your doctor or oncologist right away. To learn more about mesothelioma treatment options, download our free mesothelioma guide.
Rachel Ernst is a content writer at Mesothelioma Hub. She graduated with a Bachelor of Arts degree from the University of Illinois at Chicago, where she majored in communication and minored in sociology. She hopes to create public awareness about cancer through her writing. In her free time, Rachel likes to be outdoors, watch movies, and spend time with her animals.
Chemocare. (n.d.). Vinorelbine. Retrieved on September 12, 2019, from http://chemocare.com/chemotherapy/drug-info/Vinorelbine.aspx
DrugBank. (2005). Vinorelbine. Retrieved on September 12, 2019, from https://www.drugbank.ca/drugs/DB00361
Faller, B., et. al. (2011). Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clinical Medicine Insights: Oncology. Retrieved on September 12, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117629/
International Drug Price Indicator Guide. (n.d.). Vinorelbine. Retrieved on September 12, 2019, from http://mshpriceguide.org/en/single-drug-information/?DMFId=1668&searchYear=2014
OncoLink. (n.d.) Vinorelbine. Retrieved on September 12, 2019, from https://www.oncolink.org/cancer-treatment/oncolink-rx/vinorelbine-navelbine-r
U.S. National Library of Medicine. (2014). Vinorelbine in Mesothelioma (VIM). Retrieved on September 12, 2019, from https://clinicaltrials.gov/ct2/show/NCT02139904
World Health Organization. (n.d.) Essential medicines and health products. Retrieved on September 12, 2019, from https://www.who.int/medicines/en/
World Health Organization. (2015). WHO Model List of Essential Medicines. Retrieved on September 12, 2019, from https://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1